Servatus Ltd's CEO Dr Wayne Finlayson discusses the company's recent $7.5 million capital raise to advance its live microbial and engineered protein biotherapeutics drug development. He says two phase 1/2 clinical trials are due to launch shortly in Queensland - for insomnia and rheumatoid arthritis - which will complement existing trials in inflammatory bowel disease, H. pylori infection and IBS-C / chronic constipation.
Servatus talks $7.5 million raise to advance its microbial biotherapeutics clinical programs
